INS and type 1 diabetes mellitus: In the EASE (Empagliflozin as Adjunctive to inSulin thErapy) trials, empagliflozin at 10 and 25 mg, as well as a unique dose of 2.5 mg, in addition to intensive insulin therapy in people with type 1 diabetes was evaluated.